Supporting Publications
ZN-d5 (BCL-2 Inhibitor)
A Phase 1/2 multi-center dose finding study to assess PK and efficacy of ZN-d5, a novel BCL-2 inhibitor for treatment of subjects with relapsed/refractory AL amyloidosis
Kastritis, E. et al. (2022) American Society of Hematology
Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models
Izadi, H. et al. (2022) American Association for Cancer Research
A Phase 1 dose-escalation study of ZN-d5, a BCL-2 inhibitor with improved selectivity, in subjects with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
Zaucha, J. et al. (2021) European Society for Medical Oncology
Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Pinchman, J. et al. (2021) European Society for Medical Oncology